
PSTV Stock Forecast & Price Target
PSTV Analyst Ratings
Bulls say
Plus Therapeutics Inc exhibits a strong positive outlook due to its focused advancement in drug development, particularly with its lead candidate rhenium (186Re) obisbemeda, which has shown promising preliminary results in treating central nervous system cancers. The company is projected to experience a substantial increase in CNSiderelated revenues, expecting to reach approximately $1 million in 2025 and grow significantly to $38 million by 2032, driven by increasing adoption and state licensing. Additionally, the receipt of an $18 million grant from the Cancer Prevention and Research Institute of Texas positions Plus Therapeutics well to further its research and potential market reach in addressing leptomeningeal metastases.
Bears say
The analysis indicates a negative outlook for Plus Therapeutics Inc. primarily due to several risks associated with its product development. The potential failure of key candidates to prove safety and efficacy, coupled with uncertainties surrounding regulatory approvals and reimbursement, undermines investor confidence. Additionally, the dilution resulting from an equity raise has further impacted the valuation, leading to a downward adjustment of the price target from $3.00 to $2.00 per share.
This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
PSTV Analyst Forecast & Price Prediction
Start investing in PSTV
Order type
Buy in
Order amount
Est. shares
0 shares